Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed
Abstract
Vedolizumab was not more effective than placebo in inducing clinical remission at week 6 among patients with CD in whom previous treatment with TNF antagonists had failed. The therapeutic benefits of vedolizumab in these patients were detectable at week 10. ClinicalTrials.gov number: NCT01224171.
Keywords
National Center for Biotechnology Information
NCBI
NLM
MEDLINE
Europe
humans
pubmed abstract
nih
national institutes of health
national library of medicine
research support
non-u.s. gov't
adult
female
male
aged
middle aged
young adult
Remission Induction
Clinical Trial
Phase III
Randomized Controlled Trial
Antibodies
Monoclonal
Double-Blind Method
Multicenter Study
north america
Brian G Feagan
Humanized / therapeutic use*
Gastrointestinal Agents / therapeutic use*
time factors
anti-inflammatory agents / therapeutic use*
bruce e sands
crohn disease / drug therapy*
anti-inflammatory agents / adverse effects
humanized / adverse effects
tumor necrosis factor-alpha / metabolism
israel
treatment failure
humanized / pharmacokinetics
crohn disease / diagnosis
crohn disease / immunology
pmid:24859203
doi:10.1053/j.gastro.2014.05.008
video-audio media
webcast
stephen hanauer
anti-inflammatory agents / pharmacokinetics
drug substitution*
gastrointestinal agents / adverse effects
gastrointestinal agents / pharmacokinetics
tumor necrosis factor-alpha / antagonists & inhibitors*
Access
Citation
ID:
271584
References
Blockchain Verification
Account:
NFT Contract Address:
0x95644003c57E6F55A65596E3D9Eac6813e3566dA
Article ID:
271584
Unique Identifier:
Network:
Scimatic Chain (ID: 481)
Loading...
Blockchain Readiness Checklist
Authors
Abstract
Journal Name
Year
Title
Creates 1,000,000 NFT tokens for this article
Token Features:
- ERC-1155 Standard NFT
- 1 Million Supply per Article
- Transferable via MetaMask
- Permanent Blockchain Record
Scan with Saymatik Web3.0 Wallet